Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3159824 | 0.87 | KDM4E (0.47) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL3148684 | 0.85 | KDM4E (0.46) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL3149706 | 0.82 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL3161819 | 0.82 | MAPK1 (0.43) | ALDH1A1LMNAMAPK1 | |
| SCHEMBL3153654 | 0.79 | KDM4E (0.46) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL3161308 | 0.77 | KDM4E (0.42) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL8658937 | 0.70 | ALDH1A1 (0.52) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL5675358 | 0.70 | KDM4E (0.67) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL3144540 | 0.69 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL3157702 | 0.68 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| EP-1224170-B1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| US-6545035-B1 | Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-08 | — | — | US | disclosed |
| US-6319918-B1 | FOR LYMPHOMA OR SOLID TUMORS TREATMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-20 | — | — | US | disclosed |